PEDIATRICS Vol. 66 No. 3 September 1980, pp. 483-484
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Balsan, S.
Right arrow Articles by Steendijk, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Balsan, S.
Right arrow Articles by Steendijk, R.

Questions on the Use of Vitamin D3

Sonia Balsan MD1 and Robert Steendijk MD2

1 Laboratoire des Tissus Calcifiés, Hôpital des Enfants Malades, 75730 Paris Cedex 15, France
2 Department of Pediatrics, University Hospital Binnengasthuis, 1012 GA Amsterdam, The Netherlands

From their observations in a boy with hypophosphatemic rickets Chan and Bartter1 conclude that administration of 1agr,25-dihydroxyvitamin D3 (1,25-(OH)2D3) is the treatment of choice for this disease. Since this point of view is not shared by everybody, it demands careful scrutiny. The conclusion rests on the increased growth velocity, the radiologic healing of the rachitic lesions, and the increase in serum phosphorus which occurred when treatment was changed from vitamin D2 to 1,25-(OH)2D3. From the growth curve of this boy it appears that the increase in growth velocity could represent the pubertal growth spurt in a late maturer.